Lobbying

Mpharma Data's latest lobbying report covers Q2 2023, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues.

Mpharma Data

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$0
Last 4 quarters
vs last quarter
No record
Q3 2026 against the quarter before
First report
Q4 2022
The first quarter a report named it

Lobbying by quarter

Mpharma Data lobbying by quarter
Mpharma Data lobbying by quarter
QuarterAmountReports
Q4 2022$30K1
Q1 2023$20K1
Q2 2023$01
Q3 2023$00
Q4 2023$00
Q1 2024$00
Q2 2024$00
Q3 2024$00
Q4 2024$00
Q1 2025$00
Q2 2025$00
Q3 2025$00
Q4 2025$00
Q1 2026$00
Q2 2026$00
Q3 2026$00

By issue

  • Health issues$50K · 2 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • Commerce, Dept of (DOC)2 reports
  • Export-Import Bank of the United States (EXIM Bank)2 reports
  • State, Dept of (DOS)2 reports
  • U.S. Agency for International Development (USAID)2 reports
  • White House Office2 reports

Firms it paid

Firm
KRL International$50K3 quarters

Former officials lobbying for it

No lobbyist with a covered position.

Lobbying reports

Filed by
23/07/10for Q2 2023KRL InternationalUnder $5,000
23/04/18for Q1 2023KRL International$20K
23/01/18for Q4 2022KRL International$30K